analysts said Pfizer’s announcement sent a bearish view on hemophilia gene therapy commercial opportunity for Sangamo, but they view the stock sell-off as “overdone since limited valuation was ...

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics ...

Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of $2.00. Discover outperforming stocks and invest smarter ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

Shares of Sangamo Therapeutics have plummeted more than 56% over the past few days after Pfizer announced it had terminated its partnership to develop an investigational gene therapy product to treat ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio has given his Buy rating ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 billion.